CVRX

Over the past six months, CVRx's stock price has decreased by 27.16%. Key events impacting the stock include the release of the Fourth Quarter and Full Year 2025 financial results on February 12, 2026, which showed a revenue increase. On January 1, 2026, new Category I CPT codes and favorable physician fee payment levels took effect. On April 13, 2026, preliminary first-quarter 2026 results were reported, showing a revenue increase and improved gross margin, leading to a positive market reaction. On May 4, 2026, the enrollment of the first patient in the BENEFIT-HF trial was announced, a landmark heart failure trial evaluating Barostim.